Presentation Details
| Factor XIII testing- what is available? what are best practices for testing? effect of concentrates on lab tests? antigen versus activity testing? any remaining role for clot solubility? Natalie Mathews. |
Abstract
Factor XIII (FXIII) deficiency is considered to be the most underdiagnosed bleeding disorder. In addition to a high index of suspicion, an understanding of the benefits and limitations of the various FXIII assays is important for making a diagnosis. A few key challenges include the varying lower limits of detection for these assays and the lack of consistent concordance between activity and antigen results. However, as demonstrated by FXIII assay data over the last 10 years from the Hamilton Regional Laboratory Program in Hamilton, Canada and the Centre Hospitalier Universitaire Sainte-Justine in Montreal, Canada, certain lessons can be learned with respect to diagnosing and monitoring patients.
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.